Preterm Labor and Fetal Sequelae: Role of Ureaplasmas

早产和胎儿后遗症:解脲支原体的作用

基本信息

  • 批准号:
    7423873
  • 负责人:
  • 金额:
    $ 35.82万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1979
  • 资助国家:
    美国
  • 起止时间:
    1979-01-01 至 2009-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The objectives of this Research Plan are to assess the efficacy of antibiotic and anti-inflammatory therapy on preterm labor and relevant sequelae of prematurity (i.e., fetal lung injury) in mobile, chronically catheterized pregnant rhesus monkeys infected intraamniotically with Ureaplasma parvum (formerly U. urealyticum serovar 1). It is our hypothesis that prenatal treatment of intrauterine ureaplasmal infection with an intravenous macrolide antibiotic combined with an anti-inflammatory agent and an immunomodulator will inhibit preterm labor, delay premature delivery, and ameliorate or prevent fetal/neonatal lung disease Physiological studies together with cellular and molecular studies of intrauterine and fetal tissues will address the following questions: (1) Does therapy with azithromycin combined with a prostaglandin synthesis inhibitor (indomethacin) and with dexamethasone inhibit intraamniotic microbial growth and downregulate the cytokine/prostaglandin cascade? (2) Do these interventions prevent preterm labor and fetal lung disease without adverse fetal side-effects? The effect of no treatment, antibiotic therapy, and combined antibiotic/anti-inflammatory therapy on preterm labor and fetal sequelae will be compared. A number of endpoints will be ascertained to establish links among ureaplasma infections, preterm labor, fetal lung injury and the response to therapy including potential fetal side-effects (e.g., intraventricular hemorrhage, enterocolitis). Continuous recordings of uterine contractility will be correlated with amniotic fluid levels of prostaglandins, cytokines, leukocytes, MMPs and maternal, fetal and amniotic fluid levels of azithromycin. Quantitative cultures and PCR for ureaplasmas will be performed on amniotic fluid, blood and fetal tissues. Tissue cytokine mRNA will be quantitated by real-time PCR. Fetal lung damage will be assessed by histopathologic and immunohistochemical methods and by lung morphometry. The gastrointestinal tract, meninges and brain will be examined for inflammation. Death of oligodendrocyte progenitors and other cell types in cerebral white matter will be evaluated by immunohistochemical methods and assays for apoptosis. The work proposed is unique in its use of combined interventional strategies in a well established nonhuman primate model of intrauterine infection. The results should illuminate the causal role of ureaplasma in prematurity and lead to advances in clinical management.
DESCRIPTION (provided by applicant): The objectives of this Research Plan are to assess the efficacy of antibiotic and anti-inflammatory therapy on preterm labor and relevant sequelae of prematurity (i.e., fetal lung injury) in mobile, chronically catheterized pregnant rhesus monkeys infected intraamniotically with Ureaplasma parvum (formerly U. urealyticum serovar 1).我们的假设是,用静脉内大花环抗生素与抗炎剂和免疫调节剂相结合的宫内尿中感染和免疫调节剂相结合,会抑制早产,过早递送,并延迟过早递送或与胎儿/新生肺疾病的生理学研究:跟随胎儿疾病的生理研究: (1)阿奇霉素的治疗与前列腺素合成抑制剂(吲哚美辛)和地塞米松结合抑制了燃料内微生物的生长并下调细胞因子/前列腺素级联脉络膜吗? (2)这些干预措施是否可以预防不良胎儿副作用的早产和胎儿肺疾病?没有治疗,抗生素治疗以及抗生素/抗炎疗法对早产和胎儿后遗症的影响。将确定许多终点,以在尿素倍率感染,早产,胎儿肺损伤和对治疗的反应之间建立联系,包括潜在的胎儿副作用(例如,脑室内出血,小肠结肠炎)。子宫收缩力的连续记录将与羊水,细胞因子,白细胞,MMP以及孕妇,胎儿和羊水的羊水水平相关。将在羊水,血液和胎儿组织上进行定量培养物和PCR。组织细胞因子mRNA将通过实时PCR进行定量。胎儿肺损伤将通过组织病理学和免疫组织化学方法以及肺形态计量法评估。将检查胃肠道,脑膜和大脑的炎症。少突胶质细胞祖细胞和其他细胞类型在脑白质中的死亡将通过免疫组织化学方法和细胞凋亡的测定进行评估。提出的工作在使用宫内感染的非​​人类灵长类动物模型中使用了联合介入策略是独一无二的。结果应阐明尿素成倍率在早产中的因果作用,并导致临床管理的进步。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Juha Pekka Rasanen其他文献

Juha Pekka Rasanen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Juha Pekka Rasanen', 18)}}的其他基金

PRETERM LABOR AND FETAL SEQUELAE: ROLE OF MYCOPLASMAS
早产和胎儿后遗症:支原体的作用
  • 批准号:
    7958410
  • 财政年份:
    2009
  • 资助金额:
    $ 35.82万
  • 项目类别:

相似国自然基金

小细胞肺癌脑、肾上腺等多器官转移的谱系可塑性机制与干预研究
  • 批准号:
    82330087
  • 批准年份:
    2023
  • 资助金额:
    220 万元
  • 项目类别:
    重点项目
STAT5促进肾上腺素生成介导髓系造血及肿瘤免疫抑制的机制研究
  • 批准号:
    82372908
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
慢性压力刺激调控释放的肾上腺素影响TAMs极化促进结肠癌进展的机制研究
  • 批准号:
    82303327
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
内皮β3肾上腺素能受体调控线粒体功能参与血管衰老的作用研究
  • 批准号:
    82370408
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
SARS-CoV-2刺突蛋白作为β肾上腺素受体配体介导心脏炎症和纤维化的机制研究
  • 批准号:
    82300295
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Aldosterone/mineralocorticoid receptor responses to biologic sex and salt intake: Role of Lysine Specific Demethylase 1 (LSD1)
醛固酮/盐皮质激素受体对生物性别和盐摄入量的反应:赖氨酸特异性脱甲基酶 1 (LSD1) 的作用
  • 批准号:
    10930190
  • 财政年份:
    2023
  • 资助金额:
    $ 35.82万
  • 项目类别:
A Safer Glucocorticoid to Treat Neonatal Lung Injury with Limited Adverse Neurologic Effects
一种更安全的糖皮质激素治疗新生儿肺损伤且不良神经系统影响有限
  • 批准号:
    10312167
  • 财政年份:
    2021
  • 资助金额:
    $ 35.82万
  • 项目类别:
A Safer Glucocorticoid to Treat Neonatal Lung Injury with Limited Adverse Neurologic Effects
一种更安全的糖皮质激素治疗新生儿肺损伤且不良神经系统影响有限
  • 批准号:
    10656485
  • 财政年份:
    2021
  • 资助金额:
    $ 35.82万
  • 项目类别:
Pharmacogenomics of Adrenal Suppression with Inhaled Corticosteroids (PhASIC)
吸入皮质类固醇抑制肾上腺的药物基因组学 (PhASIC)
  • 批准号:
    10394312
  • 财政年份:
    2020
  • 资助金额:
    $ 35.82万
  • 项目类别:
Pharmacogenomics of Adrenal Suppression with Inhaled Corticosteroids (PhASIC)
吸入皮质类固醇抑制肾上腺的药物基因组学 (PhASIC)
  • 批准号:
    10620657
  • 财政年份:
    2020
  • 资助金额:
    $ 35.82万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了